Business Wire

STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

Share

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326396951/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment. (Photo: Business Wire)

The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples. Such cell-type-specific enrichment can increase the sensitivity of downstream in vitro diagnostic tests for multiple myeloma—a cancer of plasma cellsto better inform patient risk and course of treatment. Accounting for approximately 2% of all cancers in the United States1, multiple myeloma is incurable, and variable or low frequencies of CD138+ cells in bone marrow samples can impact the reliability of detecting genetic abnormalities that influence the disease’s progression. Incorporation of STEMCELL's new kit in a pre-analytical step of the diagnostic workflow can contribute to improving patient care and outcomes by enhancing the sensitivity and resolution of these downstream assays.

“STEMCELL is proud to develop the first hematopoietic cell enrichment product identified as an in vitro diagnostic device by the FDA,” said Dr. Allen Eaves, President and CEO, STEMCELL. “Creating an IVD product that improves the accuracy of information guiding the treatment of patients with multiple myeloma is a milestone achievement that reflects our commitment to make a positive impact on human health.”

The FDA identifies this new product type as a hematopoietic cell enrichment kit: a Class II IVD device for selecting specific cells from human whole blood or bone marrow, intended for use with diagnostic assays as part of the pre-analytical workflow. Agencies such as the National Comprehensive Cancer Network and the American College of Medical Genetics recommend CD138+ cell enrichment upstream of fluorescence in situ hybridization (FISH) testing for multiple myeloma; however, until now, hematopoietic cell enrichment products have not been classified as IVD devices by the FDA.

“This De Novo classification will have a permanent impact on the IVD landscape and paves the way for further innovation,” said Dr. Eaves. “STEMCELL is committed to building on this foundational work in the IVD field with novel diagnostic products and support, including supporting industry partnerships through our Diagnostics Partnerships and OEMSolutions Program.”

The EasySep™ Human Bone Marrow CD138 Positive Selection Kit is part of STEMCELL’s portfolio of EasySep™ immunomagnetic cell isolation technologies, specifically developed for fast and easy isolation of highly purified cells that are ready for downstream applications. It marks the culmination of many years of work, which included examining more than 230 bone marrow aspirates from multiple myeloma patients, precision studies of inter- and intra-laboratory reproducibility, and limit of detection and interference studies. The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.

1Padala et al. 2021 Med Sci (Basel)

About STEMCELL Technologies

STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
For more information and to arrange an interview, contact:
Ryan-Sang Lee, Director, Corporate Communications and Media Relations, STEMCELL Technologies | public.relations@stemcell.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Release First Quarter 2024 Results on May 6, 202416.4.2024 22:15:00 CEST | Press release

IFF (NYSE:IFF) today announced that it will release its first quarter 2024 earnings results following the market close on Monday, May 6, 2024. The management team will host a live webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more goo

A new chapter for Medisca: Sanjay D. Goorachurn appointed as Chief Executive Officer16.4.2024 19:58:00 CEST | Press release

Medisca, a global company specializing in personalized pharmaceutical solutions, is pleased to announce the appointment of Sanjay D. Goorachurn as the company’s new CEO, as founders, Tony Dos Santos and Maria Zaccardo, transition into strategic advisory roles as Chair and Vice Chair, respectively. Coinciding with the company’s 35th anniversary, this decision marks a significant milestone in Medisca’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416663563/en/ Left to right: Tony Dos Santos, Founder | Maria Zaccardo, Co-founder | Sanjay D. Goorachurn, CEO (Photo: Business Wire) In 1989, Medisca opened its doors as a team of three with two products and a vision to bridge the gaps in patient care. Today, Medisca is a global leader in personalized medicine with more than 10 locations spanning 5 countries. Powered by a workforce of over 450 employees, Medisca offers a vast portfolio of more than 2,000 product solutio

Bona Releases 2023 Sustainability Report16.4.2024 18:00:00 CEST | Press release

Bona®, a global, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, today released its Sustainability Report for 2023. This year, Bona has included a narrative summary of its sustainability progress following by its audited statutory sustainability report. This is another important step by Bona to move its sustainability efforts forward and align with the demands of the Corporate Sustainability Reporting Directive (CSRD). “We are currently in the midst of developing our sustainability work in line with our ambitions and stakeholder expectations. This year’s report reflects this ongoing journey and presents many examples of the progress we are making, among which are our advances in reducing fossil-based plastics in our packaging, the introduction of bio-based products, and the launch of our Sustainability Board,” said Magnus Andersson, Bona CEO. Most notably, Bona announced in its report the establishment of a Sustai

Unforgettable Experiences Await: Secure Your Spot at NPE202416.4.2024 16:42:00 CEST | Press release

Anticipation for the largest plastics trade show in the Americas is nearly over; registration for NPE2024: The Plastics Show closes in less than a month. Held in the Orange County Convention Center in Orlando, Florida, the show spans over 1.1 million net square feet of exhibit space. NPE2024 will be the most impactful trade show of the year for all plastics industry sectors in the U.S. and globally, with more than 55,000 professionals expected and over 2,100 exhibitors. Attendees will come from over 115 countries, representing the entire plastics ecosystem and nearly every part of the global industry. NPE2024 is back, and a completely reimagined experience. The show’s slogan “Made For You,” highlights its focus on personalization, offering various education, networking and innovation for professionals in the automotive, building and construction, consumer products, packaging and medical industries. NPE2024 is returning bigger and better than ever with the announcement of new features s

Lenovo Embraces the AI PC Era with New ThinkCentre Desktops Powered by AMD Ryzen PRO 8000 Series Desktop Processors16.4.2024 15:00:00 CEST | Press release

Lenovo™ has unveiled a selection of ThinkCentre™ desktops powered by AMD Ryzen™ PRO 8000 Series desktop processors with up to 16 TOPS (trillion operations per second) of integrated NPU capability dedicated to process AI workloads, including the performance focused ThinkCentre M75t Gen 5, the flexible ThinkCentre M75s Gen 5, and the compact ThinkCentre M75q Gen 5. Designed to meet the diverse needs of modern business, the ThinkCentre M75 Gen 5 family of desktops harnesses the AI capability of its component while optimizing its energy efficiency to deliver impressive results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416990902/en/ Lenovo ThinkCentre M75s Gen 5 (Photo: Business Wire) “The AI PC era is already here and at Lenovo we are embracing it to unlock new possibilities,” said Sanjeev Menon, vice president and general manager, Worldwide Desktop Business in Intelligent Devices Group, Lenovo. “The need for businesses

HiddenA line styled icon from Orion Icon Library.Eye